LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Champions Oncology Inc

Geschlossen

BrancheGesundheitswesen

5.7 -1.55

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.7

Max

5.93

Schlüsselkennzahlen

By Trading Economics

Einkommen

702K

236K

Verkäufe

1M

15M

KGV

Branchendurchschnitt

35.765

110.024

Gewinnspanne

1.57

Angestellte

213

EBITDA

1.1M

612K

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+97.37% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

10. März 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-23M

84M

Vorheriger Eröffnungskurs

7.25

Vorheriger Schlusskurs

5.7

Nachrichtenstimmung

By Acuity

50%

50%

165 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Champions Oncology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Feb. 2026, 22:31 UTC

Ergebnisse

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. Feb. 2026, 22:18 UTC

Ergebnisse

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. Feb. 2026, 22:11 UTC

Ergebnisse

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. Feb. 2026, 21:52 UTC

Ergebnisse

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. Feb. 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. Feb. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. Feb. 2026, 23:34 UTC

Market Talk
Ergebnisse

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. Feb. 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. Feb. 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. Feb. 2026, 22:45 UTC

Ergebnisse

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. Feb. 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. Feb. 2026, 22:37 UTC

Ergebnisse

Nutrien 4Q EPS $1.18 >NTR.T

18. Feb. 2026, 22:37 UTC

Ergebnisse

Nutrien 4Q Sales $5.34B >NTR.T

18. Feb. 2026, 22:35 UTC

Ergebnisse

Pan American Silver 4Q EPS $1.07 >PAAS

18. Feb. 2026, 22:35 UTC

Ergebnisse

Pan American Silver 4Q Rev $1.18B >PAAS

18. Feb. 2026, 22:30 UTC

Ergebnisse

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. Feb. 2026, 22:29 UTC

Ergebnisse

Kinross Gold 4Q EPS 75c >K.T

18. Feb. 2026, 22:22 UTC

Ergebnisse

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. Feb. 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. Feb. 2026, 22:16 UTC

Ergebnisse

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. Feb. 2026, 22:05 UTC

Ergebnisse

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. Feb. 2026, 22:03 UTC

Ergebnisse

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q Sales $929M >KALU

18. Feb. 2026, 22:02 UTC

Ergebnisse

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. Feb. 2026, 22:00 UTC

Ergebnisse

Kinross Gold 4Q Adj EPS 67c >KGC

18. Feb. 2026, 22:00 UTC

Ergebnisse

Kinross Gold 4Q Sales $2.02B >KGC

18. Feb. 2026, 21:56 UTC

Ergebnisse

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Champions Oncology Inc Prognose

Kursziel

By TipRanks

97.37% Vorteil

12-Monats-Prognose

Durchschnitt 12 USD  97.37%

Hoch 12 USD

Tief 12 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Champions Oncology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

5.77 / 7.61Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

165 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
help-icon Live chat